Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 19/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ATXN2 | Q99700 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047218 | 0.96 | ENPP2 (0.47) | ENPP2KCNH2ATXN2 | |
| SCHEMBL170045 | 0.89 | ENPP2 (0.46) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11967651 | 0.88 | ENPP2 (0.35) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11967643 | 0.84 | ENPP2 (0.36) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11967678 | 0.82 | FAAH (0.33) | — | |
| SCHEMBL11899086 | 0.81 | ENPP2 (0.48) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11899214 | 0.81 | ENPP2 (0.48) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11899299 | 0.81 | ENPP2 (0.38) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11899298 | 0.81 | ENPP2 (0.38) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11962595 | 0.80 | ENPP2 (0.42) | ENPP2KCNH2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193118-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | MERCK PATENT GMBH (DE) | 2012-08-22 | — | — | EP | claimed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | claimed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2193118-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | MERCK PATENT GMBH (DE) | 2012-08-22 | — | — | EP | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | ENPP2 3706/4885KCNH2 66/4885ATXN2 3403/4885 |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | ENPP2 3706/4885KCNH2 66/4885ATXN2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.